Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
To evaluate the clinical efficacy of community-based azithromycin treatment for individuals with suspected COVID-19 at increased risk of adverse outcomes.
Randomized, controlled, open-label, adaptive platform trial (PRINCIPLE) conducted in primary care settings across the UK.
Evaluated oral azithromycin versus standard care in community patients with suspected COVID-19 presenting with risk factors for severe disease.
Assessed time to clinical recovery and rates of hospital admission or death associated with outpatient azithromycin use.
Determined the therapeutic utility of azithromycin for routine early intervention against suspected SARS-CoV-2 in community settings.
Abstract
UK Research and Innovation and UK Department of Health and Social Care.